MCID: ELP001
MIFTS: 37

Elephantiasis

Categories: Immune diseases

Aliases & Classifications for Elephantiasis

MalaCards integrated aliases for Elephantiasis:

Name: Elephantiasis 12 76 55 3 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4976
MeSH 44 D004604
NCIt 50 C34569
UMLS 73 C0013882

Summaries for Elephantiasis

CDC : 3 People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.

MalaCards based summary : Elephantiasis is related to filarial elephantiasis and podoconiosis. An important gene associated with Elephantiasis is NF1 (Neurofibromin 1), and among its related pathways/superpathways is Cell adhesion_Cell-matrix glycoconjugates. The drugs Ivermectin and Albendazole have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and bone.

Wikipedia : 76 Elephantiasis is the enlargement and hardening of limbs or body parts due to tissue swelling. It is... more...

Related Diseases for Elephantiasis

Diseases related to Elephantiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 filarial elephantiasis 34.0 GPT2 SRCIN1
2 podoconiosis 33.2 INSRR SLC24A5
3 loiasis 31.7 MFF SRCIN1
4 lymphedema 11.4
5 hydrocele 11.4
6 filariasis 10.4
7 lymphangitis 10.3
8 cerebral aneurysms 10.2 ELANE ELN
9 mid-dermal elastolysis 10.2 ELANE ELN
10 cerebral arterial disease 10.1 ELN NF1
11 status asthmaticus 10.1 ELANE RNASE3
12 alpha-1-antitrypsin deficiency 10.1 ELANE ELN
13 bacterial pneumonia 10.1 ELANE ELN
14 bronchopulmonary dysplasia 10.1 ELANE RNASE3
15 pulmonary emphysema 10.1 ELANE ELN
16 adult respiratory distress syndrome 10.1 ELANE ELN
17 neurofibromatosis, type i 10.1
18 erysipelas 10.1
19 onchocerciasis 10.1
20 lymphadenitis 10.1
21 hidradenitis suppurativa 10.1
22 hidradenitis 10.1
23 lymphangiosarcoma 10.1
24 inguinal hernia 10.1 ELN NF1
25 senile ectropion 10.1 ELN SRCIN1
26 bronchial disease 10.1 ELANE RNASE3
27 sclerosing keratitis 10.1 MFF SRCIN1
28 deep keratitis 10.1 MFF SRCIN1
29 bronchitis 10.1 ELANE RNASE3
30 aortic aneurysm, familial abdominal, 1 10.0 ELANE ELN
31 morbid obesity 10.0
32 neurofibroma 10.0
33 anterior scleritis 10.0 MFF SRCIN1
34 proteasome-associated autoinflammatory syndrome 1 10.0 ELANE RNASE3
35 pulmonary disease, chronic obstructive 10.0 ELANE ELN RNASE3
36 neurofibrosarcoma 10.0 INSRR NF1
37 lung disease 10.0 ELANE ELN RNASE3
38 respiratory system disease 10.0 ELANE RNASE3
39 angiosarcoma 9.9
40 venous insufficiency 9.9
41 sarcoma 9.9
42 graves' disease 9.9
43 lymphogranuloma venereum 9.9
44 congenital lymphedema 9.9
45 autosomal dominant disease 9.9 ELANE NF1
46 kaposi sarcoma 9.8
47 lichen sclerosus et atrophicus 9.8
48 neurofibromatosis, type iv, of riccardi 9.8
49 scleroderma, familial progressive 9.8
50 neural tube defects 9.8

Graphical network of the top 20 diseases related to Elephantiasis:



Diseases related to Elephantiasis

Symptoms & Phenotypes for Elephantiasis

Drugs & Therapeutics for Elephantiasis

Drugs for Elephantiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 70288-86-7 6474909
2
Albendazole Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54965-21-8 2082
3
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-89-1 3052
4
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 564-25-0 54671203
5
Azithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 83905-01-5 55185 447043
6
Praziquantel Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 55268-74-1 4891
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Anthelmintics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Lipoxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Antimalarials Phase 4,Phase 3,Phase 2
15 Anticonvulsants Phase 4
16
Petrolatum Approved, Investigational Phase 3 8009-03-8
17
Glycerol Approved, Investigational Phase 3 56-81-5 753
18 Disinfectants Phase 3
19 Protective Agents Phase 3
20 Eusol Phase 3
21 Sodium hypochlorite Phase 3
22 Vitamins Phase 3
23 Milbemycin Phase 3,Phase 2
24 Reslizumab Approved, Investigational Phase 2
25
Rifampicin Approved Phase 2 13292-46-1 5458213 5381226
26
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
27
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
28 Artemisinine Phase 2
29 Artemisinins Phase 2
30 Anti-Asthmatic Agents Phase 2
31 Antibodies, Monoclonal Phase 2
32 Antibodies Phase 2
33 Respiratory System Agents Phase 2
34 Immunoglobulins Phase 2
35 Antitubercular Agents Phase 2
36 Antibiotics, Antitubercular Phase 2
37 Cytochrome P-450 CYP3A Inducers Phase 2
38 Nucleic Acid Synthesis Inhibitors Phase 2
39 Imatinib Mesylate Phase 2 220127-57-1 123596
40 Protein Kinase Inhibitors Phase 2
41
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
42 Pharmaceutical Solutions Phase 1
43
Mebendazole Approved, Vet_approved 31431-39-7 4030
44
Piperazine Approved, Vet_approved 110-85-0 4837
45
Permethrin Approved, Investigational Not Applicable 52645-53-1 40326
46
Citric Acid Approved, Nutraceutical, Vet_approved 77-92-9 311
47
Suramin Investigational 145-63-1 5361
48 Citrate
49 Piperazine citrate
50 Liver Extracts Not Applicable

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
3 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
4 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy Completed NCT03052998 Phase 4 Ivermectin
5 Twice Yearly Treatment for the Control of LF Recruiting NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
6 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 4 Albendazole
7 Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
8 Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
9 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Withdrawn NCT02734186 Phase 4 Praziquantel
10 An RCT to Evaluate the Effect of a New Skin Care Regimen on SBF in Those With Podoconiosis Completed NCT02839772 Phase 3
11 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
12 IVM Alone vs ALB + IVM Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
13 Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection Completed NCT00790998 Phase 3 Moxidectin;Ivermectin
14 A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali Recruiting NCT02927496 Phase 3 Doxycycline;Placebo
15 A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka Recruiting NCT02929134 Phase 3 Doxycycline;Placebo
16 Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana Active, not recruiting NCT02078024 Phase 3 IVM plus ALB;IVM
17 A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India Not yet recruiting NCT02929121 Phase 3 Doxycycline;Placebo
18 Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Not yet recruiting NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
19 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
20 Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis Completed NCT00340691 Phase 2 Doxycycline
21 Effect of Albendazole Dose on Clearance of Filarial Worms Completed NCT00339417 Phase 2 Albendazole;Ivermectin
22 Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
23 Effect of Albendazole Dose on Clearance of Filarial Worms Completed NCT00375583 Phase 2 DEC/Albendazole
24 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
25 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
26 Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2 2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin
27 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed NCT00127504 Phase 2 Rifampin;Azithromycin
28 Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana Completed NCT02281643 Phase 2 Doxycycline
29 PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs ) Not yet recruiting NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
30 Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa Not yet recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
31 Pediatric Pharmacokinetics And Safety Study Of Moxidectin Withdrawn NCT01035619 Phase 2 moxidectin
32 Relative Bioavailability Study of Emodepside IR-tablets and Solution Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
33 First in Man Clinical Trial of Emodepside (BAY 44-4400) Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
34 Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside Recruiting NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
35 Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE) Active, not recruiting NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
36 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
37 Exhaled NO Testing in Filariasis Completed NCT01628497
38 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
39 Research for Elim of Filariasis Completed NCT00145223
40 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
41 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
42 Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
43 Interaction Between HIV and Lymphatic Filariasis Completed NCT00295698 Not Applicable Diethylcarbamazine
44 Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 Not Applicable 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
45 Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area Completed NCT00139100 Not Applicable antimicrobial agent in soap
46 Medical Implications of Coinfection With Malaria and Filariasis Parasites Completed NCT00471666
47 Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination Completed NCT01586169 Not Applicable triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
48 Prevalence of LF Infection in Districts Not Included in LF Control Activities Completed NCT03131401
49 Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis Completed NCT00344279
50 Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis Completed NCT01160523

Search NIH Clinical Center for Elephantiasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Elephantiasis

Anatomical Context for Elephantiasis

MalaCards organs/tissues related to Elephantiasis:

41
Skin, Lymph Node, Bone, Testes, Thyroid, Heart, Lung

Publications for Elephantiasis

Articles related to Elephantiasis:

(show top 50) (show all 550)
# Title Authors Year
1
Warty Fingers and Toes in a Child With Congenital Lymphedema: Elephantiasis Nostras Verrucosa. ( 29710245 )
2018
2
Unsuspected Amelanotic Melanoma in an Elephantiasis Foot. ( 29854646 )
2018
3
Bilateral vulval filarial elephantiasis. ( 29472427 )
2018
4
Treatment of elephantiasis of the leg by fasciotomy and lymphangiectomy with skin preservation in a resource-limited setting: a case report and review. ( 29616640 )
2018
5
Bilateral Lower Limb and Abdominal Elephantiasis Due to Erysipelas. ( 29578137 )
2018
6
Podoconiosis: Nonfilarial endemic elephantiasis. ( 29371058 )
2018
7
The Successful Treatment of Elephantiasis Nostras Verrucosa With Ablative Carbon Dioxide Laser. ( 29519146 )
2018
8
Angiosarcoma complicating lower leg elephantiasis in a male patient: An unusual clinical complication, case report and literature review. ( 30397474 )
2018
9
Peno-Scrotal Elephantiasis Nostras Verrucosa: Rare Disorder in a Young Nigerian. ( 30027999 )
2018
10
Acitretin may improve symptoms and exudation in patients affected by elephantiasis nostras verrucosa: Report of a case. ( 30549253 )
2018
11
Giant elephantiasis and inguino-scrotal hernia. ( 28617809 )
2017
12
Wuchereria bancrofti infection at four primary schools and surrounding communities with no previous blood surveys in northern Uganda: the prevalence after mass drug administrations and a report on suspected non-filarial endemic elephantiasis. ( 28814926 )
2017
13
Beta Human Papillomavirus Infection Is Prevalent in Elephantiasis and Exhibits a Productive Phenotype: A Case-Control Study. ( 28253203 )
2017
14
A Case of Exuberant Elephantiasis Nostras Verrucosa. ( 28865510 )
2017
15
Elephantiasis nostras verrucosa. ( 29067989 )
2017
16
Elephantiasis nostras verrucosa secondary to recurrent erysipelas. ( 28838924 )
2017
17
Elephantiasis nostras verrucosa: a rare complication of lower limb lymphoedema. ( 28847994 )
2017
18
Erratum to: Wuchereria bancrofti infection at four primary schools and surrounding communities with no previous blood surveys in northern Uganda: the prevalence after mass drug administrations and a report on suspected non-filarial endemic elephantiasis. ( 28943776 )
2017
19
Left Ulnar Artery Pseudoaneurysm and Left Hand Swelling Simulated by Elephantiasis in a Patient with Neurofibromatosis Type 1. ( 30065469 )
2017
20
Elephantiasis nostras verrucosa secondary to congestive cardiac failure. ( 26944379 )
2016
21
Elephantiasis Nostras Verrucosa. Excision with full-thickness skin grafting of the penis, scrotum, and perineal area. ( 27900063 )
2016
22
Evolution of Skin during Rehabilitation for Elephantiasis Using Intensive Treatment. ( 27999691 )
2016
23
Giant elephantiasis neuromatosa in the setting of neurofibromatosis type 1: A case report. ( 27284375 )
2016
24
Abdominal Elephantiasis Nostras Verrucosa: An Underrecognized Disorder. ( 27784526 )
2016
25
Scroto-perineal hidradenitis suppurativa complicated by giant scrotal elephantiasis. ( 25837812 )
2015
26
Liposuction Normalizes Lymphedema Induced Adipose Tissue Hypertrophy in Elephantiasis of the Leg - A Prospective Study with a Ten-Year Follow-Up. ( 26397659 )
2015
27
Successful Surgical Treatment for Elephantiasis Nostras Verrucosa Using a New Designed Column Flap. ( 25573979 )
2015
28
The diagnostic challenge of mapping elephantiasis in the Tigray region of northern Ethiopia. ( 26518364 )
2015
29
Vulval elephantiasis. ( 26500880 )
2015
30
Elephantiasis nostras verrucosa occurring in voluntary shut-in ("hikikomori"). ( 25500212 )
2015
31
Resolution of septic shock in a patient with myelomeningocele (spina bifida) complicated with deforming Elephantiasis Nostras Verrucosa. ( 25623264 )
2015
32
A case of progressive elephantiasis nostras verrucosa. ( 25832960 )
2015
33
Scrotal elephantiasis secondary to recalcitrant hidradenitis suppurativa. ( 26087097 )
2015
34
Verrucous lesions arising in lymphedema and diabetic neuropathy: Elephantiasis nostras verrucosa or verrucous skin lesions on the feet of patients with diabetic neuropathy? ( 26281791 )
2015
35
Epidemiology of elephantiasis with special emphasis on podoconiosis in Ethiopia: A literature review. ( 26119541 )
2015
36
Massive Soft Tissue Neurofibroma (Elephantiasis Neuromatosa): Case Report and Review of Literature. ( 25694465 )
2015
37
Clinical Reasoning: A 50-year-old man with "elephantiasis" and headache. ( 26598438 )
2015
38
NF1 truncating mutations associated to aggressive clinical phenotype with elephantiasis neuromatosa and solid malignancies. ( 24922668 )
2014
39
Elephantiasis nostras verrucosa. ( 24682133 )
2014
40
Debulking surgery for elephantiasis nostras with large ectatic podoplanin-negative lymphatic vessels in patients with lipo-lymphedema. ( 24741382 )
2014
41
Recurrent unilateral vulval elephantiasis: a case report. ( 24971141 )
2014
42
Elephantiasis nostras verrucosa as a manifestation of morbid obesity. ( 25406220 )
2014
43
Photoclinic. Elephantiasis nostras verrucosa secondary to lymphedema praecox. ( 24979570 )
2014
44
Elephantiasis nostras verrucosa of lower limb: a case report. ( 25369015 )
2014
45
Maggot Therapy for Elephantiasis Nostras Verrucosa Reveals New Applications and New Complications: A Case Report. ( 24861094 )
2014
46
How 'The association of endemic elephantiasis of the lower legs in East Africa with soil derived from volcanic rocks' has underpinned progress in podoconiosis research. ( 25059525 )
2014
47
Excision of Elephantiasis Nostras Verrucosa Lesions in a Patient With Hereditary Lymphedema: Case Report and Review of the Literature. ( 25441846 )
2014
48
Images in clinical medicine. Elephantiasis nostras verrucosa. ( 24963571 )
2014
49
Elephantiasis nostras verrucosa. ( 24856044 )
2014
50
Modelling environmental factors correlated with podoconiosis: a geospatial study of non-filarial elephantiasis. ( 24946801 )
2014

Variations for Elephantiasis

Expression for Elephantiasis

Search GEO for disease gene expression data for Elephantiasis.

Pathways for Elephantiasis

Pathways related to Elephantiasis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.21 ELANE ELN

GO Terms for Elephantiasis

Cellular components related to Elephantiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 azurophil granule lumen GO:0035578 8.96 ELANE RNASE3
2 axon GO:0030424 8.8 INSRR NF1 SRCIN1

Biological processes related to Elephantiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.16 ELANE SLC24A5
2 antimicrobial humoral response GO:0019730 8.96 ELANE RNASE3
3 skeletal muscle tissue development GO:0007519 8.62 ELN NF1

Sources for Elephantiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....